Literature DB >> 15710974

Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?

D S Pardi1, W J Sandborn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15710974      PMCID： PMC1774419          DOI： 10.1136/gut.2004.048850

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  17 in total

Review 1.  Faecal parameters in the assessment of activity in inflammatory bowel disease.

Authors:  A van der Sluys Veer; I Biemond; H W Verspaget; C B Lamers
Journal:  Scand J Gastroenterol Suppl       Date:  1999

2.  Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders.

Authors:  A G Røseth
Journal:  Dig Liver Dis       Date:  2003-09       Impact factor: 4.088

3.  Predictability of the postoperative course of Crohn's disease.

Authors:  P Rutgeerts; K Geboes; G Vantrappen; J Beyls; R Kerremans; M Hiele
Journal:  Gastroenterology       Date:  1990-10       Impact factor: 22.682

4.  Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease.

Authors:  F Costa; M G Mumolo; L Ceccarelli; M Bellini; M R Romano; C Sterpi; A Ricchiuti; S Marchi; M Bottai
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

5.  A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease.

Authors:  C Brignola; M Campieri; G Bazzocchi; P Farruggia; A Tragnone; G A Lanfranchi
Journal:  Gastroenterology       Date:  1986-12       Impact factor: 22.682

Review 6.  Intestinal permeability: an overview.

Authors:  I Bjarnason; A MacPherson; D Hollander
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

7.  Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease.

Authors:  A G Røseth; P N Schmidt; M K Fagerhol
Journal:  Scand J Gastroenterol       Date:  1999-01       Impact factor: 2.423

8.  Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease.

Authors:  S Schreiber; S Nikolaus; J Hampe; J Hämling; I Koop; B Groessner; H Lochs; A Raedler
Journal:  Lancet       Date:  1999-02-06       Impact factor: 79.321

9.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

Authors:  J Y Mary; R Modigliani
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

10.  The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study.

Authors:  M Boirivant; M Leoni; D Tariciotti; S Fais; O Squarcia; F Pallone
Journal:  J Clin Gastroenterol       Date:  1988-08       Impact factor: 3.062
View more
  16 in total

1.  DNA Methylation Profiling in Inflammatory Bowel Disease Provides New Insights into Disease Pathogenesis.

Authors:  Edel McDermott; Elizabeth J Ryan; Miriam Tosetto; David Gibson; Joe Burrage; Denise Keegan; Kathryn Byrne; Eimear Crowe; Gillian Sexton; Kevin Malone; R Alan Harris; Richard Kellermayer; Jonathan Mill; Garret Cullen; Glen A Doherty; Hugh Mulcahy; Therese M Murphy
Journal:  J Crohns Colitis       Date:  2015-09-28       Impact factor: 9.071

2.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.

Authors:  T Kaiser; J Langhorst; H Wittkowski; K Becker; A W Friedrich; A Rueffer; G J Dobos; J Roth; D Foell
Journal:  Gut       Date:  2007-08-03       Impact factor: 23.059

3.  Calprotectin and IBD.

Authors:  M Lemann; J Y Mary
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

4.  Soluble Syndecan-1: Does This Biomarker Address a Seemingly Insoluble Problem in Inflammatory Bowel Disease?

Authors:  Angela M Patterson
Journal:  Dig Dis Sci       Date:  2015-04-25       Impact factor: 3.199

5.  Predicting Outcomes and Tailoring Therapy in the Diagnosis and Treatment of IBD.

Authors:  Ellen J Scherl; Ernest G Seidman; Douglas C Wolf
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-12

6.  Intestinal protein expression profile identifies inflammatory bowel disease and predicts relapse.

Authors:  Jun Shen; Yuqi Qiao; Zhihua Ran; Tianrong Wang; Jiangtao Xu; Jinsun Feng
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

7.  Predicting Hospitalization and Outpatient Corticosteroid Use in Inflammatory Bowel Disease Patients Using Machine Learning.

Authors:  Akbar K Waljee; Rachel Lipson; Wyndy L Wiitala; Yiwei Zhang; Boang Liu; Ji Zhu; Beth Wallace; Shail M Govani; Ryan W Stidham; Rodney Hayward; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2017-12-19       Impact factor: 5.325

Review 8.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

Review 9.  Diagnosis of inflammatory bowel disease: Potential role of molecular biometrics.

Authors:  Amosy E M'Koma
Journal:  World J Gastrointest Surg       Date:  2014-11-27

10.  Subclinical intestinal inflammation in siblings of children with Crohn's disease.

Authors:  Mimi Pham; Steven T Leach; Daniel A Lemberg; Andrew S Day
Journal:  Dig Dis Sci       Date:  2010-10-08       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.